With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
In support of American Diabetes Month®, Colgate Total kicked-off the “Small Steps Make a Big Difference” campaign to help raise awareness surrounding the often overlooked association between oral health and diabetes.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7332551-colgate-total-american-diabetes-association-small-steps-make-a-big-difference-campaign/
Extremely painful and destructive, gout is the most common form of inflammatory arthritis with elevated serum uric acid (sUA) a root cause of the disease. Even with the growing incidence of gout, recent research from the Gout & Uric Acid Education Society (GUAES) found that just 16 percent of Americans overall know the target sUA number for gout (6 mg/dL or below) – and just 38 percent of people with gout had their sUA levels checked within the past six months, the timeframe recommended by the American College of Rheumatology. Additionally, the majority of gout sufferers don’t understand the importance of taking daily uric acid-lowering medications, with four in 10 incorrectly believing that they can stop taking medications when they aren’t experiencing flares.
Seeking to increase recognition of the severity of gout and need for routine sUA testing and management, GUAES hosted a professional roundtable discussion on October 3, 2015. The roundtable brought together several experts – rheumatologists, a family care physician, and representatives from the American Association of Diabetes Educators, the National Kidney Foundation and CreakyJoints – to explore how to more effectively educate about gout and improve access to public education and treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7715851-guaes-gout-roundtable-discussion/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today issued a new challenge to the millions of Americans affected by type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. In 2015, award-winning artist Tim McGraw, celebrated actress S. Epatha Merkerson and chef Leticia Moreinos Schwartz each shared their personal connection to type 2 diabetes. This year, they’re calling on people to share their stories.
Living with diabetes isn’t easy, and that’s why America’s Diabetes Challenge encourages people with type 2 diabetes to work with their doctor to set and reach their A1C goal. The program will aim to identify the most common challenges patients submit and will offer tips to help address them. The program is also designed to help people learn if they’re at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785551-merck-americas-diabetes-challenge/
Se pone en marcha el primer estudio integral a largo plazo que compara diferentes medicaciones para el tratamiento de la diabetes tipo 2 a escala nacional. El estudio GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness - Estrategias para la reducción de la glucemia en la diabetes: una comparativa de la eficacia) comparará los efectos beneficiosos y riesgos a largo plazo de cuatro fármacos ampliamente utilizados en el tratamiento de la diabetes, en combinación con metformina, la medicación de primera línea más frecuente para tratar la diabetes tipo 2. El estudio GRADE está buscando voluntarios latinos.
Para ver el Multimedia News Release, vaya a http://www.multivu.com/mnr/65066-nih-grade-study-on-type-2-diabetes-medication-seeks-latino-volunteers
Four students with four unique experiences, residing in three different countries. What do they all have in common? They have either completed or are on the path of completing the entire Kumon Math and Reading Program, which ends with critical reading and calculus. Their mastery of self-learning and ability to study above grade level has led them to achieve remarkable heights at such a young age.
Meet Jessica, at 10-years-old she speaks six languages and dreams of becoming a fiction writer one day.
Meet Elina, 14-years-old. She won a national architecture competition that asked students to design a model for future schools.
Meet Etash, at 16-years-old he has already created and published two apps, won the 2017 Congressional App Challenge for Colorado and was invited to Washington DC by his congressman.
Meet Jesica, 20-years-old. She is researching accessible and inexpensive solutions for diabetes—Mexico’s number one cause of death—in the diabetes lab at the National Autonomous University of Mexico.
To view the multimedia release go to:
https://www.multivu.com/players/English/8238652-kumon-2018-inspirational-student-videos/
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Today, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced the launch of ‘Cuida tu Don,’ a national public awareness initiative featuring legendary entertainer Mario Kreutzberger, better known as ‘Don Francisco.’ Kreutzberger, who has type 2 diabetes, will serve as an ambassador for the initiative and encourage Hispanics with type 2 diabetes to live a lifestyle conducive to staying healthy. ‘Cuida tu Don,’ translated as ‘Take Care of Your Gift,’ is designed to engage, educate and inspire Hispanics with type 2 diabetes and their families. The initiative provides resources and information in three key aspects of diabetes – nutrition, fitness and treatment options – to the estimated 3.2 million Hispanics in the United States with the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7401451-boehringer-ingelheim-diabetes/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
